CCL

Összesen 13 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM132031
Első szerző:Barna Sándor (kutató orvos)
Cím:Artificial Intelligence Based CT-free Attenuation Correction in Adolescent and Young Adult Mandibular Condylar Hyperplasia Patients / Barna Sándor, Szoliková Melinda, Csikos Csaba, Török Judit, Husztik Borbála, Varga József, Kovács Ákos, Garai Ildikó
Dátum:2024
ISSN:1619-7070 1619-7089
Megjegyzések:Aim/Introduction: Mandibular condylar hyperplasia is a condition in which one of the mandibular condyles is growing faster than the one on the other side resulting in facial asymmetry. It might be accompanied by chewing dysfunction or dental malocclusion. The cornerstone of diagnosis is 99mTc-MDP bone scan and SPECT/CT. Quantitative analysis of the uptake values can further improve diagnostic accuracy, however, standardized uptake values (SUV) can only be generated with CT-based attenuation correction (AC) which gives unnecessary radiation exposure to patients. AI-based AC could help us eliminate unnecessary radiation while providing sufficient data for quantification. Our aim was to compare the SUV values of patients with condylar hyperplasia using CT-based attenuation correction (CT-AC) and an AI-based synthetic CT attenuation correction (SynCT-AC). Materials and Methods: SUVmax and SUVmean values of 13 patients (12 female, 1 male + mean age 24) were measured using both CT-based and AI-based attenuation correction. 600MBq 99mTc-MDP iv. administered and 120view, 128matrix size SPECT and Low-Dose CT were done. The reconstruction method was OSEM-3D-RR with attenuation and scatter correcton based on original CT and SynCT. Reference SUV values (clivus, calvaria, vertebra) were also measured. SUV values were measured using 2 cm diameter volume of interests (VOIs). Correlation between CT-AC and Sy-CT-AC was measured in all reference areas and in the mandibles as well. Significance of the differences between CT-AC and Sy-CT-AC based uptake values were analyzed using paired t-test (in case of Gaussian distribution) and Wilcoxon signed rank test. To visualized the difference in the parameters of Sy-CT-AC and CT-based AC, Bland-Altman plots and box-and-whiskers plots were created. Results: The CT-AC and SyCT-AC based uptake values correlated well (r2 is above 0.93) in all cases. Mandibular and vertebral SUVs turned out to be biased since both SUVmax and SUVmean values were higher with AI-based AC. SUVmax values of the mandibles and vertebrae had a proportional error with AI, meaning the difference in SUVs from CT-based AC is greater at higher SUV values. The relative mandibular uptakes were not biased. Ratios of SUVmax values resulted in less deviation from the CT-based values. Conclusion: AI-based attenuation correction can be a promising tool in patient evaluation for mandibular condylar hyperplasia, since it provides appropriate quantitative analysis while avoiding unnecessary CT dose We detected high correlation between CT-based and AI-based SUV values. Further studies need to be conducted to elucidate the difference at higher SUV values.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:European Journal Of Nuclear Medicine And Molecular Imaging. - 51 : Suppl. 1 (2024), p. S778-S779. -
További szerzők:Szolikova, Melinda Csikos Csaba (1997-) (orvos) Török Judit (1973-) (egyetemi tanársegéd, fogszakorvos) Husztik Borbála Varga József (1955-) (fizikus) Kovács Ákos Garai Ildikó (1966-) (radiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM136552
Első szerző:Csikos Csaba (orvos)
Cím:The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer / Csikos Csaba, Varga Antal, Molnár Szabolcs, Hascsi Zsolt, Bátyi Ferenc, Garai Ildikó, Krasznai Zoárd Tibor
Dátum:2026
ISSN:1471-2407
Megjegyzések:Background Secondary cytoreductive surgery is a feasible treatment option in recurrent ovarian cancer. Patient selection for surgery remains challenging, as conventional imaging, such as CT and MRI, is unreliable for predicting complete gross resection. PET/CT is a modality that combines metabolic and anatomical imaging. Although there are studies supporting the use of PET/CT in ovarian cancer, there is very limited evidence specifically assessing PET/CT-guided selection for secondary cytoreductive surgery under the latest eligibility criteria. This study aims to evaluate the added value of PET/CT for predicting no residual tumor volume after secondary surgical cytoreduction. Methods We conducted a retrospective data collection on patients diagnosed with ovarian cancer who underwent a PET/CT examination between 2018 and 2023 in our center. Patients with suspected recurrence considered for secondary cytoreduction based on conventional imaging and clinical criteria, were included in our analysis. Besides descriptive statistics we performed decision curve analysis (DCA) to determine the added value of PET/CT in surgical decision-making. Results 22 patients were potentially eligible for secondary debulking according to clinical criteria and conventional imaging findings. 13/22 patients were found to be operable based on preoperative PET/CT results, and 11/13 had a successful resection (no gross residual tumor) (PPV: 85%). 9/22 patients were found ineligible for secondary cytoreduction based on PET/CT results. 7/9 had inoperable lesions, and in two cases, no malignant lesions were detected. Decision curve analysis showed that PET/CT provided superior clinical utility compared to both conventional imaging and a "treat none" approach, yielding a higher net benefit across a broad range of surgical decision thresholds. Conclusions Our results demonstrate that PET/CT adds significant clinical value in selecting appropriate candidates for secondary cytoreduction, mainly by reinforcing potential operability. These findings suggest that PET/CT may provide incremental information during preoperative assessment; however, prospective validation is required.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
recurrent ovarian cancer
secondary debulking surgery
complete cytoreduction
[18F]FDG
PET/CT
preoperative prediction
Megjelenés:BMC Cancer. - [Epub ahead of print] (2026). -
További szerzők:Varga Antal (2000-) (orvostanhallgató) Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Hascsi Zsolt Bátyi Ferenc Garai Ildikó (1966-) (radiológus) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász)
Pályázati támogatás: TKP2021-EGA-19
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM136480
035-os BibID:(wos)001726941400001
Első szerző:Csikos Csaba (orvos)
Cím:Enhanced Tumor-to-Background Contrast with [52Mn]Mn-BPPA-Bevacizumab VEGF-Targeted Immuno-PET in Cervical Cancer / Csikos Csaba, Ngo Minh Toan, Vágner Adrienn, Nagy Gábor, Ország Gábor, Nagy Tamás, Váradi Balázs, Sajtos Gergő Zoltán, Kapus István, Szoboszlai Zoltán, Szikra Dezső, Tircsó Gyula, Krasznai Zoárd Tibor, Molnár Szabolcs, Garai Ildikó, Trencsényi György
Dátum:2026
ISSN:1424-8247
Megjegyzések:Background/Objectives: Radiolabeled bevacizumab-based immuno-PET tracers enable a non-invasive quantification of VEGF-A expression in gynecologic malignancies. While the previously reported [52Mn]Mn-DOTAGA-bevacizumab demonstrated selective VEGF-A-targeted uptake in a KB-3-1 cervix carcinoma mouse model, further improvements in chelator stability and tumor-to-background contrast remain desirable. The recently developed BPPA chelator exhibits exceptionally high Mn(II) complex stability and favorable radiolabeling characteristics. This study aimed to characterize the in vivo biodistribution of [52Mn]Mn-BPPA-bevacizumab, and to compare the tumor-to-background ratios of [52Mn]Mn-BPPA-bevacizumab with the previously published values of [52Mn]Mn-DOTAGA-bevacizumab in VEGF-A-expressing cervix carcinoma. Methods: Female KB-3-1 tumor-bearing CB17 SCID mice underwent PET/MRI imaging following intravenous administration of [52Mn]Mn-BPPA-bevacizumab. SUVmean values were measured in various organs and in the subcutaneously injected tumor, and tumor-to-organ ratios were calculated at various time points up to 10 days post-injection. Results: [52Mn]Mn-BPPA-bevacizumab demonstrated sustained tumor uptake, with tumor SUVmean values increasing from approximately 1.0 at 4 h to peak values of approximately 2.4?2.5 at 72 h post-injection. Tumor-to-background ratios increased progressively over time and were significantly higher for [52Mn]Mn-BPPA-bevacizumab compared with previously reported [52Mn]Mn-DOTAGA-bevacizumab, particularly for tumor-to-blood, tumor-to-liver and tumor-to-lung ratios at later imaging time points (p < 0.0001). Conclusions: The novel [52Mn]Mn-BPPA-bevacizumab tracer exhibits satisfactory in vitro and in vivo stability for PET imaging, high VEGF-A-specific tumor uptake, and markedly improved tumor-to-background ratios compared to the previously published DOTAGA-based probe. These results position [52Mn]Mn-BPPA-bevacizumab as a highly promising next-generation immuno-PET agent for imaging VEGF-A-expressing gynecologic malignancies and for guiding anti-angiogenic therapies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
52Mn
chelator
BPPA
bevacizumab
cervical cancer
immuno-PET
PET/MRI
VEGF
Megjelenés:Pharmaceuticals. - 19 : 3 (2026), p. 1-16. -
További szerzők:Ngo, Minh Toan (1995-) (orvos) Vágner Adrienn (1990-) (vegyész, kémikus) Nagy Gábor (1990-) (radiokémikus, vegyész) Ország Gábor Nagy Tamás (1977-) (vegyész, orvosi laboratóriumi analitikus) Váradi Balázs (1990-) (vegyész) Sajtos Gergő Zoltán (1999-) (okleveles vegyész) Kapus István (vegyész) Szoboszlai Zoltán (1980-) (fizikus) Szikra Dezső Péter (1983-) (vegyész) Tircsó Gyula (1977-) (vegyész, kémia tanár) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász) Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Garai Ildikó (1966-) (radiológus) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus)
Pályázati támogatás:NKFIH K-134694
Egyéb
ADVANCED 152778
Egyéb
EKÖP-24-0
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM134398
Első szerző:Csikos Csaba (orvos)
Cím:PET/CT-Guided Patient Selection for Secondary Cytoreduction in Recurrent Ovarian Cancer / C. Csikos, A. Varga, Z. Hascsi, S. Molnár, Z. T. Krasznai, I. Garai
Dátum:2025
ISSN:3051-2913
Megjegyzések:Aim/Introduction: Secondary cytoreductive surgery (SCS) may improve survival in recurrent ovarian cancer, but patient selection remains challenging. Conventional imaging modalities (CT, MRI) are limited in predicting complete surgical success. Our prior meta-analysis suggested that a favorable PET/CT result could predict complete cytoreduction in almost 90% of the cases [1]. This study aimed to evaluate the added value of PET/CT in preoperative assessment for SCS. Materials and Methods: We retrospectively reviewed 196 patients with ovarian cancer who underwent [18F]FDG PET/CT between 2018-2023 in our clinic. Of these, 22 patients with recurrent ovarian cancer were eligible for SCS based on conventional imaging, and also underwent [18F] FDG PET/CT as part of the preoperative assessment. Diagnostic performance metrics were calculated, and decision curve analysis (DCA) was performed to assess the clinical utility of PET/ CT in guiding surgical decision-making. Results: Among the 22 patients selected for SCS based on conventional imaging, PET/ CT prevented surgery in 9/22 patients by identifying findings suggestive of inoperability. Of the 13 patients who were considered operable by PET/CT and underwent surgery, 11/13 had complete cytoreduction (PPV: 84.6%). PET/CT demonstrated superior clinical utility in decision curve analysis compared to both a "treat all" and a "treat none" strategy, offering greater net benefit across a wide range of surgical thresholds. As an operable state on conventional imaging was the initial inclusion criterion for surgery, it functioned as the "treat all" approach in this analysis. Conclusion: Our findings confirm that preoperative PET/CT can provide clinically meaningful value in selecting candidates for secondary cytoreduction. PET/CT results improved decision-making and offered a higher net benefit compared to conventional imaging. These results support the finding of our prior meta-analysis in which a high positive predictive value of PET/CT was found in this setting. Our results suggest that PET/CT may be a useful tool to evaluate patient eligibility for secondary cytoreduction of recurrent ovarian cancer and avoid non-beneficial interventions. References: 1. Csikos C, Czina P, Molnár S, Kovács AR, Garai I, Krasznai ZT. Predicting Complete Cytoreduction with Preoperative [18F]FDG PET/CT in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis. Diagnostics. 2024;14(16):1740. https:// doi.org/10.3390/diagnostics14161740.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:EANM Innovation. - 1 (2025), p. S573. -
További szerzők:Varga Antal (2000-) (orvostanhallgató) Hascsi Zsolt Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász) Garai Ildikó (1966-) (radiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM132028
035-os BibID:(WoS)001332779400001
Első szerző:Csikos Csaba (orvos)
Cím:Validation of an AI-Based Noise Reduction Filter on Bone Scan Images / Csikos Csaba, Barna Sándor, Kovács Ákos, Budai Ádám, Szoliková Melinda, Nagy Iván, Husztik Borbála, Kiszler Gábor, Garai Ildikó
Dátum:2024
ISSN:1619-7070 1619-7089
Megjegyzések:Aim/Introduction: Artificial intelligence (AI) is a promising tool in helping physician workflow and raise the effectiveness of their reads. Our work focuses on the validation of an AI based tool developed by Kovacs et al., 2022. In our validation, we aimed to evaluate the performance of an AI-based noise reduction filter. Materials and Methods: The AI bone scan filter (BS-AI) was validated retrospectively on 99mTc-MDP whole body images. The examinations were performed according to the institutional routine protocol. Validation was done using 47 planar bone scans of different patients which form a representative group of the training set. 3 nuclear medicine experts scored AI-filtered and original images for image quality and contrast. The performance of the BS-AI filter was tested on artificially degraded noisy images - 75-50-25% of total counts - which were generated by binominal sampling. For quantitative analysis, we used an automatic lesion detector (BS-annotator). The total number of lesions detected by the BS-annotator in the BS-AI filtered low-count images were compared to the original filtered images. The total number of pixels in the filtered low-count images relative to the number of pixels in the original filtered images were compared with one-way ANOVA. Results: Based on visual assessment, observers agreed that image contrast and quality were better in the BS-AI filtered images, increasing their diagnostic confidence. In addition, no new or disappearing lesions were detected in the filtered total- count and in the images degraded to counts of 75% and 50%. However, new and disappearing lesions were detected in images degraded to a count of 25%. The similarities of lesions detected by BS-annotator compared to filtered total-count images were 89%, 83%, 75% for images degraded to counts of 75%, 50% and 25%. There was no significant difference in the number of annotated pixels between filtered images with different counts. Conclusion: Our results showed that this BS-AI noise reduction filter is able to improve image quality and contrast not only on images with conventional protocol but also on low-count images. The use of this filter may provide an opportunity to reduce acquisition time or decrease the injected dose. References: Kovacs A, Bukki T, Legradi G, et al. Robustness analysis of denoising neural networks for Bone Scintigraphy. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2022;1039:167003.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:European Journal of Nuclear Medicine and Molecular Imaging. - 51 : Suppl. 1 (2024), p. S787. -
További szerzők:Barna Sándor (1982-) (kutató orvos) Kovács Ákos Budai Ádám Szolikova, Melinda Nagy Iván Gábor Husztik Borbála Kiszler Gábor Garai Ildikó (1966-) (radiológus)
Pályázati támogatás:EKÖP-24-3-II
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM126339
035-os BibID:(scopus)85211822029 (wos)001377328800001
Első szerző:Csikos Csaba (orvos)
Cím:AI-Based Noise-Reduction Filter for Whole-Body Planar Bone Scintigraphy Reliably Improves Low-Count Images / Csikos Csaba, Barna Sándor, Kovács Ákos, Czina Péter, Budai Ádám, Szoliková Melinda, Nagy Iván Gábor, Husztik Borbála, Kiszler Gábor, Garai Ildikó
Dátum:2024
ISSN:2075-4418
Megjegyzések:Background/Objectives: Artificial intelligence (AI) is a promising tool for the enhancement of physician workflow and serves to further improve the efficiency of their diagnostic evaluations. This study aimed to assess the performance of an AI-based bone scan noise-reduction filter on noisy, low-count images in a routine clinical environment. Methods: The performance of the AI bone-scan filter (BS-AI filter) in question was retrospectively evaluated on 47 different patients' 99mTc-MDP bone scintigraphy image pairs (anterior- and posterior-view images), which were obtained in such a manner as to represent the diverse characteristics of the general patient population. The BS-AI filter was tested on artificially degraded noisy images?75, 50, and 25% of total counts?which were generated by binominal sampling. The AI-filtered and unfiltered images were concurrently appraised for image quality and contrast by three nuclear medicine physicians. It was also determined whether there was any difference between the lesions seen on the unfiltered and filtered images. For quantitative analysis, an automatic lesion detector (BS-AI annotator) was utilized as a segmentation algorithm. The total number of lesions and their locations as detected by the BS-AI annotator in the BS-AI-filtered low-count images was compared to the total-count filtered images. The total number of pixels labeled as lesions in the filtered low-count images in relation to the number of pixels in the total-count filtered images was also compared to ensure the filtering process did not change lesion sizes significantly. The comparison of pixel numbers was performed using the reduced-count filtered images that contained only those lesions that were detected in the total-count images. Results: Based on visual assessment, observers agreed that image contrast and quality were better in the BS-AI-filtered images, increasing their diagnostic confidence. Similarities in lesion numbers and sites detected by the BS-AI annotator compared to filtered total-count images were 89%, 83%, and 75% for images degraded to counts of 75%, 50%, and 25%, respectively. No significant difference was found in the number of annotated pixels between filtered images with different counts (p > 0.05). Conclusions: Our findings indicate that the BS-AI noise-reduction filter enhances image quality and contrast without loss of vital information. The implementation of this filter in routine diagnostic procedures reliably improves diagnostic confidence in low-count images and elicits a reduction in the administered dose or acquisition time by a minimum of 50% relative to the original dose or acquisition time.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
bone scan
nuclear medicine
imaging
noise reduction filter
artificial intelligence
Megjelenés:Diagnostics. - 14 : 23 (2024), p. 1-11. -
További szerzők:Barna Sándor (1982-) (kutató orvos) Kovács Ákos Czina Péter Budai Ádám Szolikova, Melinda Nagy Iván Gábor Husztik Borbála Kiszler Gábor Garai Ildikó (1966-) (radiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM123331
035-os BibID:(scopus)85202639288
Első szerző:Csikos Csaba (orvos)
Cím:Predicting Complete Cytoreduction with Preoperative [18F]FDG PET/CT in Patients with Ovarian Cancer : a Systematic Review and Meta-Analysis / Csikos Csaba, Czina Péter, Molnár Szabolcs, Kovács Anna, Garai Ildikó, Krasznai Zoárd
Dátum:2024
ISSN:2075-4418
Megjegyzések:The cornerstone of ovarian cancer treatment is complete surgical cytoreduction. The gold-standard option in the absence of extra-abdominal metastases and intra-abdominal inoperable circumstances is primary cytoreductive surgery (CRS). However, achieving complete cytoreduction is challenging, and only possible in a selected patient population. Preoperative imaging modalities such as [18F]FDG PET/CT could be useful in patient selection for cytoreductive surgery. In our sys- tematic review and meta-analysis, we aimed to evaluate the role of preoperative [18F]FDG PET/CT in predicting complete cytoreduction in primary and secondary debulking surgeries. Publications were pooled from two databases (PubMed, Mendeley) with predefined keywords "(ovarian cancer) AND (FDG OR PET) AND (cytoreductive surgery)". The quality of the included studies was assessed with the Prediction model Risk Of Bias Assessment Tool (PROBAST). During statistical analysis, MetaDiSc 1.4 software and the DerSimonian?Laird method (random effects models) were used. Primary and secondary cytoreductive surgeries were evaluated. Pooled sensitivities, specificities, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated and statistically ana- lyzed. Results were presented in forest plot diagrams and summary receiver operating characteristic (SROC) curves. Overall, eight publications were included in our meta-analysis. Four publications presented results of primary, three presented results of secondary cytoreductions, and two presented data related to both primary and secondary surgery. Pooled sensitivities, specificities, and positive and negative predictive values were the following: in the case of primary surgeries: 0.65 (95% CI 0.60?0.71), 0.73 (95% CI 0.66?0.80), 0.82 (95% CI 0.77?0.87), 0.52 (95% CI 0.46?0.59); and in the case of secondary surgeries: 0.91 (95% CI 0.84?0.95), 0.48 (95% CI 0.30?0.67), 0.88 (95% CI 0.81?0.93), 0.56 (95% CI 0.35?0.75), respectively. The PPVs of [18F]FDG PET/CT proved to be higher in cases of secondary debulking surgeries; therefore, it can be a valuable predictor of complete successful secondary cytoreduction.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ovarian cancer
cytoreductive surgery
preoperative [18F]FDG PET/CT
complete debulking
prediction
Megjelenés:Diagnostics. - 14 : 16 (2024), p. 1-14.-
További szerzők:Czina Péter Molnár Szabolcs (1987-) (szülész-nőgyógyász szakorvos) Kovács Anna Rebeka (1993-) (általános orvos) Garai Ildikó (1966-) (radiológus) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM106800
035-os BibID:(WoS)000916972400001 (Scopus)85146808735
Első szerző:Csikos Csaba (orvos)
Cím:In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model / Csaba Csikos, Adrienn Vágner, Gábor Nagy, Ibolya Kálmán-Szabó, Judit P. Szabó, Minh Toan Ngo, Zoltán Szoboszlai, Dezső Szikra, Zoárd Tibor Krasznai, György Trencsényi, Ildikó Garai
Dátum:2023
ISSN:2075-4418
Megjegyzések:Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e.g., 52Mn) with longer half-lives are the best candidates for isotope conjugation. The aim of our preclinical study was to assess the biodistribution and tumor-targeting potential of 52Mn-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed by using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [52Mn]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
52Mn
bevacizumab
cervix carcinoma
positron emission tomography
VEGF
Megjelenés:Diagnostics. - 13 : 2 (2023), p. 236-. -
További szerzők:Vágner Adrienn Nagy Gábor Kálmán-Szabó Ibolya (1980-) (molekuláris biológus) Péli-Szabó Judit (1977-) (vegyész) Ngo, Minh Toan (1995-) (orvos) Szoboszlai Zoltán (1980-) (fizikus) Szikra Dezső Péter (1983-) (vegyész) Krasznai Zoárd Tibor (1973-) (szülész-nőgyógyász, gyermeknőgyógyász) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus) Garai Ildikó (1966-) (radiológus)
Pályázati támogatás:NKFIH K119552
Egyéb
TKP2020-NKA-04
Egyéb
EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
KDP-2021
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM134396
Első szerző:Einieh, M.
Cím:Integrating Whole-Body Bone SPECT and AI-Synthetic CT in the Evaluation of Non-Oncologic Disorders / Einieh M., Barna S., Budai Á., Ország G., Csikos C., Garai I.
Dátum:2025
ISSN:3051-2913
Megjegyzések:Aim/Introduction: Multiphase regional bone SPECT/CT is an established method for assessing inflammatory, degenerative, and postoperative changes in non-oncological bone conditions. However, in some cases, patients' symptoms do not correlate with regional findings. This study evaluates the added diagnostic value of whole-body SPECT with AI-generated synthetic CT for detecting clinically relevant abnormalities beyond the primary region of interest. Materials and Methods: A total of 135 patients (mean age: 63.9 ? 14.3 years; female-to-male ratio 2:1) underwent multiphase SPECT/CT for non-oncological indications, including orthopedic (n=71), rheumatologic (n=31), neurosurgical (n=8), and other (n=11) conditions. All patients received BMI-adjusted 500-600 MBq [Tc-99m]-MDP. Early- and late-phase regional SPECT/ CT was followed by whole-body SPECT to assess uptake outside the initial region. When extra-regional uptake was observed, AI- generated synthetic CT aided anatomical localization. 8 patients were excluded due to loss of clinical follow-up, and 13 were excluded from the whole bone SPECT evaluation due to having only planar bone scans. Diagnostic performance (sensitivity, specificity) and correlation analyses (chi-square, Pearson's regression) were conducted. Results: Regional SPECT/CT showed strong diagnostic value. Orthopedic indications had a sensitivity of 92% and a specificity of 95% (hip: 96%/78%, knee: 80%/89%). Rheumatologic cases showed 100% sensitivity and 67% specificity. Neurosurgical and other groups showed no false negatives, while the latter experienced two false positives. Whole-body SPECT detected pathological uptake beyond the primary region in 69 of 122 cases (56%), significantly correlating with clinical true positives (?? = 3.39, p = 0.066). Vertebral accumulations (41), rib hot spots (13), and joint uptakes (33) were common. Among 27 patients with true positive results for metal implant loosening, 13 had incidental dental uptake (?? = 3.43, p = 0.064). We found no significant correlation (r = -0.110, p = 0.386) between the time since surgery and positive findings. Conclusion: Multiphase regional SPECT/CT offers high diagnostic reliability for non- oncological bone and joint symptoms. Whole-body SPECT with AI-synthetic CT enhances detection of clinically relevant findings beyond the region of interest, supporting its inclusion in complex cases to guide more comprehensive care.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:EANM Innovation. - 1 (2025), p. S370-S371. -
További szerzők:Barna Sándor (1982-) (kutató orvos) Budai Ádám Ország Gábor Csikos Csaba (1997-) (orvos) Garai Ildikó (1966-) (radiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM130683
035-os BibID:(scopus)105004777197 (wos)001485499400001
Első szerző:Ngo, Minh Toan (orvos)
Cím:HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab / Ngo Toan Minh, Vágner Adrienn, Nagy Gábor, Ország Gábor, Nagy Tamás, Szoboszlai Zoltán, Csikos Csaba, Váradi Balázs, Trencsényi György, Tircsó Gyula, Garai Ildikó
Dátum:2025
ISSN:1219-4956 1532-2807
Megjegyzések:Purpose: Positron emission tomography (PET) hybrid imaging targeting HER2 requires antibodies labelled with longer half-life isotopes. With a suitable radiation profile, 52Mn coupled with DOTAGA as a bifunctional chelator is a potential candidate. In this study, we investigated the tumor HER2 specificity and the temporal biodistribution of the [52Mn]Mn-DOTAGA(anhydride)-trastuzumab in preclinical models. Methods: PET/MRI and PET/CT were performed on SCID mice bearing orthotopic and ectopic HER2-positive and ectopic HER2-negative tumors at 4, 24, 48, 72, and 120 h post-injection with [52Mn]Mn-DOTAGA(anhydride)-trastuzumab. Melanoma xenografts were included for comparison of specificity. Results: In vivo biodistribution demonstrated strong contrast in HER2-positive tumors, particularly in orthotopic tumors, where uptake was significantly higher than in the blood pool and other organs from 24 h onwards and consistently higher than in ectopic HER2-positive tumors at all time points. Significantly higher tumor-to-blood and tumor-to-muscle ratios were observed in HER2-positive ectopic tumors compared to HER2-negative tumors but only at 4 and 24 h; the differences were likely due to non-specific binding of the tracer. The ratios for orthotopic HER2-positive tumors were significantly higher than those for ectopic HER2-negative tumors and melanoma at all time points. However, the differences between HER2-positive and HER2-negative tumors decreased at later time points. Conclusion: These results suggest that [52Mn]Mn-DOTAGA(anhydride)-trastuzumab demonstrates efficient tumor-to-background contrast, emphasize the higher tumor uptake observed in orthotopic tumors, and highlight the influence of tumor environment characteristics on uptake.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
breast cancer
HER2
trastuzumab
positron emission tomography
52Mn
Megjelenés:Pathology & Oncology Research. - 31 (2025), p. 1-12. -
További szerzők:Vágner Adrienn (1990-) (vegyész, kémikus) Nagy Gábor (1990-) (radiokémikus, vegyész) Ország Gábor Nagy Tamás (1977-) (vegyész, orvosi laboratóriumi analitikus) Szoboszlai Zoltán (1980-) (fizikus) Csikos Csaba (1997-) (orvos) Váradi Balázs (1990-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus) Tircsó Gyula (1977-) (vegyész, kémia tanár) Garai Ildikó (1966-) (radiológus)
Pályázati támogatás:EKÖP-24-4
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM126392
035-os BibID:(scopus)85214089046 (wos)001391862100011
Első szerző:Ngo, Minh Toan (orvos)
Cím:The Relationship of Metabolic Activity and αvβ3 Receptor Expression in Aggressive Breast Cancer Subtypes Tumors : a Preliminary Report / Ngô Toàn Minh, Nagy Tamás, Szoboszlai Zoltán, Csikos Csaba, Dénes Noémi, Furka Andrea, Trencsényi György, Garai Ildikó
Dátum:2025
ISSN:0258-851X
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:In Vivo. - 39 : 1 (2025), p. 160-171. -
További szerzők:Nagy Tamás (1977-) (vegyész, orvosi laboratóriumi analitikus) Szoboszlai Zoltán (1980-) (fizikus) Csikos Csaba (1997-) (orvos) Dénes Noémi (1992-) (vegyész) Furka Andrea (1976-) (sebész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus) Garai Ildikó (1966-) (radiológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM120892
035-os BibID:(Scopus)85192275337 (WoS)001230301300001
Első szerző:Ngo, Minh Toan (orvos)
Cím:[52 Mn]Mn-BPPA-Trastuzumab : A Promising HER2-Specific PET Radiotracer / Toàn Ngô Minh, Vágner Adrienn, Nagy Gábor, Ország Gábor, Nagy Tamás, Csikos Csaba, Váradi Balázs, Sajtos Gergő Zoltán, Kapus István, Szoboszlai Zoltán, Szikra Dezső, Trencsényi György, Tircsó Gyula, Garai Ildikó
Dátum:2024
ISSN:0022-2623 1520-4804
Megjegyzések:This study aimed to develop a novel radiotracer using trastuzumab and the long-lived [52Mn]Mn isotope for HER2-targeted therapy selection and monitoring. A new Mn(II) chelator, BPPA, synthesized from a rigid bispyclen platform possessing a picolinate pendant arm, formed a stable and inert Mn(II) complex with favorable relaxation properties. BPPA was converted into a bifunctional chelator (BFC), conjugated to trastuzumab, and labeled with [52Mn]Mn isotope. In comparison to DOTA-GA-trastuzumab, the BPPA-trastuzumab conjugate exhibits a labeling efficiency with [52Mn]Mn approximately 2 orders of magnitude higher. In female CB17 SCID mice bearing 4T1 (HER2?) and MDA-MB-HER2+ (HER2+) xenografts, [52Mn]Mn-BPPA-trastuzumab demonstrated superior uptake in HER2+ cells on day 3, with a 3?4 fold difference observed on day 7. Overall, the hexadentate BPPA chelator proves to be exceptional in binding Mn(II). Upon coupling with trastuzumab as a BFC ligand, it becomes an excellent imaging probe for HER2-positive tumors. [52Mn]Mn-BPPA-trastuzumab enables an extended imaging time window and earlier detection of HER2-positive tumors with superior tumor-to-background contrast.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
PET
MRI
manganese complexes
trastuzumab
syntehsis labelling
Megjelenés:Journal Of Medicinal Chemistry. - 67 : 10 (2024), p. 8261-8270. -
További szerzők:Vágner Adrienn (1990-) (vegyész, kémikus) Nagy Gábor (1990-) (radiokémikus, vegyész) Ország Gábor Nagy Tamás Milán (1993-) (vegyész, nmr) Csikos Csaba (1997-) (orvos) Váradi Balázs (1990-) (vegyész) Sajtos Gergő Zoltán (1999-) (okleveles vegyész) Kapus István (vegyész) Szoboszlai Zoltán (1980-) (fizikus) Szikra Dezső Péter (1983-) (vegyész) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus) Tircsó Gyula (1977-) (vegyész, kémia tanár) Garai Ildikó (1966-) (radiológus)
Pályázati támogatás:Gedeon Richter Plc Gedeon Richter Ph.D. Fellowship
Egyéb
ÚNKP-22-2
Egyéb
K-134694
NKFIH
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.